IP Library Patent Application 14592786
Patent Application
App. No. 14/592,786

SYSTEM AND METHOD FOR THERAPEUTIC MANAGEMENT OF OCULAR HYPERTENSION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/592,786
Abstract

One embodiment is directed to a system for treating hypertension within the eye of a patient, comprising a light delivery element optically intercoupled between a light source and a targeted tissue structure of the eye; wherein the targeted tissue structure has been genetically modified to have light sensitive protein; and wherein exposure of the genetically modified targeted tissue structure to radiation delivered through the light delivery element modulates the contractility of the genetically modified targeted tissue structure to reduce an intraocular pressure within the eye.

Claims (27)

1 . A system for treating hypertension within the eye of a patient, comprising:

a light delivery element optically intercoupled between a light source and a targeted tissue structure of the eye;

wherein the targeted tissue structure has been genetically modified to have light sensitive protein; and

wherein exposure of the genetically modified targeted tissue structure to radiation delivered through the light delivery element modulates the contractility of the genetically modified targeted tissue structure to reduce an intraocular pressure within the eye.

2 . The system of claim 1 , wherein the light delivery element comprises a contact lens configured to directly interface with a corneal surface of the eye.

3 . The system of claim 2 , wherein the contact lens is configured to direct light incoming toward the eye to a structure selected from the group consisting of: a trabecular meshwork of the eye; and a schlemm's canal of the eye.

4 . The system of 3 , wherein the contact lens is configured to direct light incoming toward the eye through an intermediate tissue structure selected from the group consisting of: a cornea of the eye; a limbus of the eye; and a sclera of the eye.

5 . The system of claim 2 , wherein the contact lens is further configured to comprise an optical element or segment configured to reflect incoming light.

6 . The system of claim 2 , wherein the contact lens is further configured to comprise an optical element or segment configured to focus incoming light.

7 . The system of claim 2 , wherein the contact lens is further configured to comprise an optical element or segment configured to both reflect and focus incoming light.

8 . The system of claim 2 , wherein the contact lens is further configured to comprise a spectral filtering element.

9 . The system of claim 1 , wherein the light delivery element comprises an intraocular lens configured to redirect at least a portion of radiation incoming toward the eye to the targeted tissue structure of the eye.

10 . The system of claim 9 , wherein the intraocular lens comprises an implantable prosthesis.

11 . The system of claim 9 , wherein the intraocular lens is configured to direct light incoming toward the eye to a structure selected from the group consisting of: a trabecular meshwork of the eye; and a schlemm's canal of the eye.

12 . The system of 11 , wherein the intraocular lens is configured to direct light incoming toward the eye through an intermediate tissue structure selected from the group consisting of: a cornea of the eye; a limbus of the eye; and a sclera of the eye.

13 . The system of claim 9 , wherein the intraocular lens is further configured to comprise an optical element or segment configured to reflect incoming light.

14 . The system of claim 9 , wherein the intraocular lens is further configured to comprise an optical element or segment configured to focus incoming light.

15 . The system of claim 9 , wherein the intraocular lens is further configured to comprise an optical element or segment configured to both reflect and focus incoming light.

16 . The system of claim 1 , wherein the light source is coupled to a mounting structure configured to be removably coupled to the patient.

17 . The system of claim 16 , wherein the mounting structure comprises an eyeglasses frame.

18 . The system of claim 1 , wherein the light source comprises ambient light from an environment around the patient.

19 . The system of claim 1 , wherein the light sensitive protein is an opsin protein.

20 . The system of claim 19 , wherein the opsin protein is an inhibitory opsin protein.

21 . The system of claim 20 , wherein the inhibitory opsin protein is selected from the group consisting of: NpHR, eNpHR 1.0, eNpHR 2.0, eNpHR 3.0, Mac, Mac 3.0, Arch, ArchT, and iChR.

22 . The system of claim 19 , wherein the opsin protein is a stimulatory opsin protein.

23 . They system of claim 22 , wherein the stimulatory opsin protein is selected from the group consisting of: ChR2, C1V1-T, C1V1-TT, CatCh, VChR1-SFO, and ChR2-SFO.

24 . The system of claim 1 , wherein the light source is configured to produce pulses of light to be delivered to the targeted tissue structure of the eye.

Assignments (2)
SECURITY INTEREST Recorded Nov 3, 2020
From: CIRCUIT THERAPEUTICS, INC.
To: MAGICHEART INVESTMENTS, LLC
Reel/Frame 054291/0504 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2019
From: ANGELEY, DAVID; HUANG, JOYCE; ANDERSEN, DAN; FRAZIER, SHAWNALEA; THOMAS, GRIFFITH ROGER
To: CIRCUIT THERAPEUTICS, INC.
Reel/Frame 047910/0692 →